MarketCapExport financials
Caladrius Biosciences (CLBS)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Caladrius Biosciences Balance Sheet 2025-2009 | CLBS
Brief overview of Caladrius Biosciences's balance sheet structure
Balance sheet changes are traced across five available annual reports between 2021 and 2025.
Assets finished at $17.7 million versus $97 million initially, losing -81.7%. The balance sheet contracted.
Asset growth of -81.7% came with a -37.2% rise in liabilities. Financial leverage became more prominent.
The equity ratio reached 83.7% from 95.1%. A high capital share reduces dependence on liabilities.
Cash equals 89.9% of the balance sheet, compared with 25.4% five periods ago. This is the readily available cushion.
The accumulated result is -$564.7 million and remains below zero. The number alone does not explain whether losses, dividends or repurchases were the main cause.
Overall assessment
Caladrius Biosciences's balance sheet looks stretched: reliance on liabilities and a limited capital cushion increase sensitivity to weaker results.
Annual Balance Sheet Caladrius Biosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
- | - | -22.3 M | -31.7 M | -23.9 M | -15.9 M | -13.7 M | -10.3 M | -29 M | -7.91 M | -3.54 M | -2.53 M | -42 M | -9.92 M | 3.11 M | - | - |
Long Term Debt |
- | - | 137 K | 305 K | 485 K | - | - | - | - | 2.82 M | 11.4 M | 14.7 M | 3.55 M | 172 K | - | - | - |
Long Term Debt Current |
- | 137 K | 168 K | 180 K | 229 K | 370 K | 354 K | - | - | 3.13 M | 4.17 M | 1.11 M | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | 254 K | 624 K | 1.51 M | 3.87 M | 28.3 M | 12.9 M | 52 M | 18 M | 11.6 M | 38.7 M | 17.1 M | - |
Total Current Liabilities |
3.07 M | 5.61 M | 6.59 M | 6.38 M | 4.52 M | 3.51 M | 5.98 M | 5.62 M | 9.31 M | 19.5 M | 21 M | 16.2 M | 9.81 M | 9.95 M | 36.4 M | 32.9 M | - |
Total Liabilities |
3.14 M | 5.68 M | 6.8 M | 6.71 M | 5.01 M | 3.76 M | 6.6 M | 7.13 M | 13.2 M | 47.8 M | 33.9 M | 68.2 M | 27.8 M | 21.6 M | 75.2 M | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | 5.1 M | 5.35 M | 4.33 M | 1.82 M | 1.47 M | 2.44 M | 59.4 K | - |
Retained Earnings |
-565 M | -548 M | -528 M | -507 M | -453 M | -426 M | -417 M | -398 M | -382 M | -405 M | -372 M | -291 M | -236 M | -197 M | -143 M | -95.3 M | - |
Total Assets |
17.7 M | 35 M | 54.7 M | 73 M | 97 M | 36 M | 27.2 M | 44.6 M | 63.4 M | 51.8 M | 57.2 M | 126 M | 89.8 M | 54.4 M | 155 M | 143 M | - |
Cash and Cash Equivalents |
16 M | 16.2 M | 22.6 M | 32.2 M | 24.6 M | 16.5 M | 14 M | 10.3 M | 29.2 M | 14.7 M | 20.3 M | 19.2 M | 46.1 M | 13.7 M | 3.94 M | 8.47 M | 7.16 M |
Book Value |
14.6 M | 29.3 M | 47.9 M | 66.3 M | 92 M | 32.2 M | 20.6 M | 37.5 M | 50.2 M | 4.07 M | 23.3 M | 58.1 M | 62 M | 32.8 M | 80.1 M | 143 M | - |
Total Shareholders Equity |
14.9 M | 29.6 M | 48.1 M | 66.6 M | 92.3 M | 32.5 M | 20.8 M | 37.7 M | 50.5 M | 4.88 M | 23.7 M | 58.5 M | 62.5 M | 33.2 M | 62 M | 48.7 M | 57.8 M |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet Caladrius Biosciences
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | - | - | - | - | 47 K | 92 K | 137 K | 181 K | 223 K | 265 K | 305 K | 345 K | - | 421 K | 485 K | 53 K | 79 K | - | 254 K | 254 K | 254 K | - | - | - | - | - | - | - | - | - | - | - | - | 1.7 M | 2.52 M | 2.52 M | 2.52 M | 2.52 M | 10.8 M | 10.8 M | 10.8 M | 10.8 M | 13.9 M | 13.9 M | 13.9 M | 13.9 M | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 28.4 M | - | - | - | 33.9 M | - | - | - | 68.2 M | - | - | 27.3 M | 27.8 M | 12.6 M | 12.2 M | 27.8 M | 21.6 M | 11.6 M | 11.6 M | 11.6 M | 33.9 M | 33.9 M | 33.9 M | 33.9 M |
Total Liabilities |
3.04 M | 3.39 M | 4.64 M | 4.38 M | 3.88 M | 5.68 M | 4.76 M | 4.58 M | 5.5 M | 6.8 M | 5.38 M | 4.65 M | 5.62 M | 6.71 M | 6.76 M | - | 3.22 M | 5.01 M | 4.12 M | 3.94 M | 4.59 M | 3.76 M | 3.76 M | 3.76 M | 3.76 M | 6.6 M | 6.6 M | 6.6 M | 6.6 M | 7.13 M | 7.13 M | 7.13 M | 7.13 M | 13.2 M | 13.2 M | 13.2 M | 13.2 M | 30 M | 30 M | 30 M | 28.4 M | 33.9 M | 64.7 M | 33.9 M | 33.9 M | 68.2 M | 69.3 M | 68.2 M | 68.2 M | 27.8 M | - | 27.8 M | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.58 M | - | - | - | 2.45 M | - | - | 5.36 M | 5.1 M | 5.87 M | 7.23 M | 5.64 M | 5.35 M | 5.35 M | 5.35 M | 5.35 M | 4.33 M | 4.33 M | 4.33 M | 4.33 M | 1.82 M | 1.82 M | 1.82 M | 1.82 M | 1.47 M | 1.47 M | 1.47 M | 1.47 M | 1.12 M | 1.12 M | 1.12 M | 2.44 M |
Retained Earnings |
-572 M | -569 M | -562 M | -557 M | -553 M | -548 M | -543 M | -539 M | -533 M | -528 M | -523 M | -517 M | -513 M | -507 M | -501 M | - | -457 M | -453 M | -446 M | -439 M | -434 M | -426 M | -426 M | -426 M | -426 M | -417 M | -417 M | -417 M | -417 M | -398 M | -398 M | -398 M | -398 M | -382 M | -382 M | -382 M | -382 M | -405 M | -405 M | -405 M | -405 M | -372 M | -372 M | -372 M | -372 M | -291 M | -291 M | -291 M | -291 M | -236 M | -236 M | -236 M | -236 M | -197 M | -197 M | -197 M | -197 M | -143 M | -143 M | -143 M | -143 M |
Total Assets |
11 M | 14.1 M | 21.8 M | 25.2 M | 29 M | 35 M | 38.2 M | 42.6 M | 48.2 M | 54.7 M | 58.1 M | 62.4 M | 66.3 M | 73 M | 78.5 M | - | 91.5 M | 97 M | 103 M | 109 M | 115 M | 36 M | 36 M | 36 M | 36 M | 27.2 M | 27.2 M | 27.2 M | 27.2 M | 44.6 M | 44.6 M | 44.6 M | 44.6 M | 63.4 M | 63.4 M | 63.4 M | 63.4 M | 53.5 M | 53.5 M | 53.5 M | 51.8 M | 57.2 M | 57.2 M | 57.2 M | 57.2 M | 126 M | 126 M | 126 M | 126 M | 89.8 M | 89.8 M | 89.8 M | 89.8 M | 54.4 M | 54.4 M | 54.4 M | 54.4 M | 155 M | 155 M | 155 M | 155 M |
Cash and Cash Equivalents |
10.4 M | 13.1 M | 19 M | 16.8 M | 20.2 M | 16.2 M | 19.5 M | 28.3 M | 21.8 M | 22.6 M | 32.4 M | 23.7 M | 28.2 M | 32.2 M | 31.5 M | 33.3 M | 12.7 M | 24.6 M | 12.8 M | 12.9 M | 28.7 M | 16.5 M | 16.5 M | 16.5 M | 16.5 M | 14 M | 14 M | 14 M | 14 M | 10.3 M | 10.3 M | 10.3 M | 10.3 M | 29.2 M | 29.2 M | 29.2 M | 29.2 M | 7.08 M | 7.08 M | 7.08 M | 14.7 M | 18.7 M | 20.3 M | 20.3 M | 20.3 M | 19.2 M | 19.2 M | 19.2 M | 19.2 M | 46.1 M | 46.1 M | 46.1 M | 46.1 M | 13.7 M | 13.7 M | 13.7 M | 13.7 M | 3.94 M | 3.94 M | 3.94 M | 12.6 M |
Book Value |
7.99 M | 10.7 M | 17.1 M | 20.8 M | 25.1 M | 29.3 M | 33.4 M | 38 M | 42.7 M | 47.9 M | 52.7 M | 57.7 M | 60.7 M | 66.3 M | 71.8 M | - | 88.2 M | 92 M | 98.4 M | 105 M | 110 M | 32.2 M | 32.2 M | 32.2 M | 32.2 M | 20.6 M | 20.6 M | 20.6 M | 20.6 M | 37.5 M | 37.5 M | 37.5 M | 37.5 M | 50.2 M | 50.2 M | 50.2 M | 50.2 M | 23.5 M | 23.5 M | 23.5 M | 23.5 M | 23.3 M | -7.5 M | 23.3 M | 23.3 M | 58.1 M | 57 M | 58.1 M | 58.1 M | 62 M | 89.8 M | 62 M | 89.8 M | 54.4 M | 54.4 M | 54.4 M | 54.4 M | 155 M | 155 M | 155 M | 155 M |
Total Shareholders Equity |
8.24 M | 10.9 M | 17.4 M | 21 M | 25.4 M | 29.6 M | 33.4 M | 38 M | 42.7 M | 48.1 M | 52.7 M | 57.7 M | 60.7 M | 66.6 M | 71.8 M | 82.1 M | 88.2 M | 92.3 M | 98.4 M | 105 M | 110 M | 32.5 M | 32.5 M | 32.5 M | 32.5 M | 20.8 M | 20.8 M | 20.8 M | 20.8 M | 37.7 M | 37.7 M | 37.7 M | 37.7 M | 50.5 M | 50.5 M | 50.5 M | 50.5 M | 4.88 M | 4.88 M | 4.88 M | 4.88 M | 23.7 M | 23.7 M | 23.7 M | 23.7 M | 58.5 M | 58.5 M | 58.5 M | 58.5 M | 62.5 M | 62.5 M | 62.5 M | 62.5 M | 33.2 M | 33.2 M | 33.2 M | 33.2 M | 62 M | 62 M | 62 M | 62 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of Caladrius Biosciences, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Biotechnology
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Aptose Biosciences
APTO
|
- | -45.71 % | $ 1.2 M |  Canada |
 |
Krystal Biotech
KRYS
|
$ 316.58 | 0.82 % | $ 9.16 B |  USA |
 |
Nektar Therapeutics
NKTR
|
$ 35.78 | 2.25 % | $ 604 M | USA |
 |
NanoViricides
NNVC
|
$ 1.38 | 0.73 % | $ 27.9 M | USA |
 |
Grifols, S.A.
GRFS
|
$ 7.64 | 1.33 % | $ 5.19 B |  Spain |
 |
Nurix Therapeutics
NRIX
|
$ 24.42 | 0.12 % | $ 2.12 B | USA |
 |
Ocugen
OCGN
|
$ 0.78 | 0.06 % | $ 244 M | USA |
 |
Oragenics
OGEN
|
$ 0.43 | 1.69 % | $ 928 K | USA |
 |
Omeros Corporation
OMER
|
$ 16.2 | 1.95 % | $ 1.03 B | USA |
 |
ORIC Pharmaceuticals
ORIC
|
$ 12.35 | 10.18 % | $ 1.08 B | USA |
 |
Aligos Therapeutics
ALGS
|
$ 4.86 | 3.06 % | $ 48 M | USA |
 |
Alkermes plc
ALKS
|
$ 41.22 | 2.79 % | $ 6.79 B |  Irlanda |
 |
Jazz Pharmaceuticals plc
JAZZ
|
$ 210.23 | 2.28 % | $ 12.8 B | Irlanda |
 |
Phio Pharmaceuticals Corp.
PHIO
|
$ 0.87 | 0.05 % | $ 5.21 M | USA |
 |
Kymera Therapeutics
KYMR
|
$ 104.78 | 1.23 % | $ 8.85 B | USA |
 |
Praxis Precision Medicines
PRAX
|
$ 241.76 | 3.86 % | $ 5.44 B | USA |
 |
ProQR Therapeutics N.V.
PRQR
|
$ 1.31 | 0.34 % | $ 138 M |  Niderland |
 |
PTC Therapeutics
PTCT
|
$ 59.24 | 2.21 % | $ 4.71 B | USA |
 |
Arcus Biosciences
RCUS
|
$ 22.12 | 1.26 % | $ 2.38 B | USA |
 |
Larimar Therapeutics
LRMR
|
$ 1.99 | 1.51 % | $ 165 M | USA |
 |
Regeneron Pharmaceuticals
REGN
|
$ 790.74 | 0.01 % | $ 82.7 B | USA |
 |
Rafael Holdings
RFL
|
$ 1.39 | 2.8 % | $ 40.9 M | USA |
 |
REGENXBIO
RGNX
|
$ 6.93 | 4.07 % | $ 357 M | USA |
 |
Royalty Pharma plc
RPRX
|
$ 60.96 | 2.25 % | $ 26.2 B | USA |
 |
Seer
SEER
|
$ 2.03 | 0.44 % | $ 112 M | USA |
 |
PDS Biotechnology Corporation
PDSB
|
$ 1.13 | 0.62 % | $ 52.4 M | USA |
 |
SIGA Technologies
SIGA
|
$ 3.17 | 0.16 % | $ 227 M | USA |
 |
Nanobiotix S.A.
NBTX
|
$ 21.3 | 4.46 % | $ 1.02 T |  France |
 |
Syndax Pharmaceuticals
SNDX
|
$ 12.9 | 0.89 % | $ 1.12 B | USA |
 |
Soligenix
SNGX
|
$ 0.35 | 1.67 % | $ 1.82 M | USA |
 |
Intellia Therapeutics
NTLA
|
$ 11.42 | 0.71 % | $ 1.24 B | USA |
|
Nuvation Bio
NUVB
|
$ 4.45 | 1.6 % | $ 1.52 B | USA |
 |
Sarepta Therapeutics
SRPT
|
$ 17.1 | 0.03 % | $ 1.71 B | USA |
 |
Processa Pharmaceuticals
PCSA
|
$ 1.69 | 0.6 % | $ 2.21 M | USA |
 |
RedHill Biopharma Ltd.
RDHL
|
$ 0.48 | 0.2 % | $ 5.91 B |  Israel |
 |
SELLAS Life Sciences Group
SLS
|
$ 9.98 | 4.02 % | $ 1.09 B | USA |
|
Protara Therapeutics
TARA
|
$ 2.32 | 1.46 % | $ 99.4 M | USA |
 |
Relay Therapeutics
RLAY
|
$ 16.28 | 1.41 % | $ 2.79 B | USA |
 |
Pfizer
PFE
|
$ 29.58 | 0.54 % | $ 168 B | USA |
 |
Supernus Pharmaceuticals
SUPN
|
$ 37.88 | 0.5 % | $ 2.14 B | USA |
 |
Takeda Pharmaceutical Company Limited
TAK
|
$ 19.67 | 1.08 % | $ 31.1 B |  Japan |
 |
Revolution Medicines
RVMD
|
$ 177.96 | 0.22 % | $ 33.8 B | USA |
 |
Rhythm Pharmaceuticals
RYTM
|
$ 86.17 | 0.6 % | $ 5.6 B | USA |
 |
Prelude Therapeutics Incorporated
PRLD
|
$ 3.26 | 0.9 % | $ 251 M | USA |
 |
Sana Biotechnology
SANA
|
$ 2.27 | 6.22 % | $ 575 M | USA |
 |
Pulmatrix
PULM
|
$ 1.36 | 4.61 % | $ 4.97 B | USA |
 |
Zoetis
ZTS
|
$ 79.38 | 1.22 % | $ 35.2 B | USA |
 |
Ultragenyx Pharmaceutical
RARE
|
$ 14.54 | 1.81 % | $ 1.43 B | USA |
 |
XTL Biopharmaceuticals Ltd.
XTLB
|
$ 1.96 | 2.62 % | $ 1.32 B | Israel |
 |
Cleveland BioLabs, Inc.
CBLI
|
- | -7.31 % | $ 49 M | USA |